DIAGNOS Announces Voting Results of Annual Meeting of Shareholders
September 10 2021 - 1:34PM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK)
(OTCQB:DGNOF), a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces the voting results of its annual
general and special meeting of shareholders held earlier today.
Election of directors
Mr. Vincent Duhamel, Mr. André Larente, Dr. Reid
Maclellan, Mr. Francis Bellido and Mr. Robert Dunn were elected as
directors of the Corporation to hold office until the closing of
the next annual meeting of the shareholders.
Appointment of auditor
Raymond Chabot Grant Thornton LLP was
re-appointed as auditor of the Corporation for the ensuing
year.
Amendment to the stock option
plan
The disinterested shareholders of the
Corporation approved a special resolution pursuant to which the
maximum number of common shares of the Corporation that may be
issued under the stock option plan be set at 10,200,000,
representing an increase of 1,200,000 common shares.
The amendment to the Corporation’s stock option
plan remains subject to the TSX Venture acceptance.
About DIAGNOS DIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of CARA (Computer Assisted Retina
Analysis). CARA is a tele-ophthalmology platform that integrates
with existing equipment (hardware and software) and processes at
the point of care. CARA’s image enhancement algorithms make
standard retinal images sharper, clearer and easier to read. CARA
is accessible securely over the internet, and is compatible with
all recognized image formats and brands of fundus cameras, and is
EMR compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com.
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. Marc-André Massue, CFO and Secretary
DIAGNOS Inc.
Tel: 450-678-8882 ext. 235
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024